Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex dosing (ABW vs IBW) in morbidly obese patients
NCT03346070Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 5
01
Overview
A Phase 4 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Jan 2018; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03346070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346070.